Research output per year
Research output per year
Dr, BSc (Biomed), Hons, PhD
Research activity per year
Dr Eadie is an award-winning biomedical researcher and a Cancer Council South Australia Beat Cancer Project Fellow, awarded to the top two mid-career cancer researchers in South Australia (2023-current). She is an Australian Institute of Policy and Science Young Tall Poppy (2023), previous Fulbright scholar and a TEDx speaker.
Dr Eadie has been awarded >$4 million in fellowship/grant funding in the last five years, >$2 million as CIA from funding bodies including NHMRC, MRFF, Leukaemia Foundation, Cancer Council. Dr Eadie has built an international reputation as an emerging leader in the use of patient genomics to inform therapy outcomes for Acute Lymphoblastic Leukaemia (ALL) patients, evidenced by an American Society of Hematology Achievement Award (2020) and an International Thermo Fisher Cancer Research Grant (2022).
ALL is one of the biggest causes of non-traumatic death in children and relapsed T-cell ALL (T-ALL) is an extremely high risk disease. More effective, less toxic treatments are urgently needed for when a patient fails their front-line chemotherapy. Dr Eadie is SAHMRI's T-ALL research leader and her team creates humanised mouse avatars from individual patient’s leukaemic cells to use in pre-clinical drug trials. Combined with genomic sequencing to identify a patient’s leukaemia-causing mutations, these models allow Dr Eadie to discover more effective therapeutic options targeted to each individual patient’s leukaemia.
Dr Eadie's long-term research goal is to identify new and re-purposed drugs which effectively treat the different genetic lesions associated with T-ALL. Her team's findings will ultimately provide clinicians with an arsenal of alternative treatment options and hope for patients who have relapsed.
Research Focus
T-cell acute lymphoblastic leukaemia (T-ALL) is a rare but high-risk disease affecting both children and adults. T-ALL patients are universally treated with several years of toxic, high-dose, non-selective chemotherapy which is associated with significant rates of treatment related mortality. Recent improvements to chemotherapy regimens have led to better outcomes for de novo paediatric T-ALL patients. However, the principal clinical issue in ALL is treatment resistance where up to 25% of paediatric/adolescent patients relapse and experience poor overall survival. The outlook is worse for adult T-ALL patients: 40% demonstrate primary chemotherapy resistance and most older adults will die of their disease. There is a major unmet need to identify innovative and targeted therapies for use in frontline treatment regimens to prevent resistance and relapse.
Dr Eadie's research program utilises genomic sequencing to identify novel and targetable T-ALL alterations to accelerate a transition towards precision medicine to improve clinical outcomes. Dr Eadie's Research Group is part of the SAHMRI ALL Genomics and Functional Genomics/Biology Laboratory led by Prof Deborah White (leader, SAHMRI Precision Cancer Medicine Theme). Together, with the ALL bioinformatic team, Dr Eadie has curated the largest genomic sequencing database of T-ALL patients in Australia. Dr Eadie has identified novel leukaemia-causing alterations as well as new treatment options for several high-risk ALL subtypes.
PhD, Doctor of Philosophy, University of Adelaide
30 Mar 2009 → 27 Mar 2013
Award Date: 31 Jul 2013
Bachelor's Degree (Honours), Honours Degree of Bachelor of Science, University of Adelaide
17 Jan 2006 → 2 Dec 2006
Award Date: 20 Dec 2006
Bachelor's Degree, BSc (Biomed), University of Adelaide
22 Jan 2003 → 2 Dec 2005
Award Date: 22 Dec 2005
Affiliate Senior Lecturer Discipline of Medicine, University of Adelaide
Apr 2020 → …
Post Doctoral Research Associate, St. Jude Children Research Hospital
14 Aug 2016 → 15 Aug 2017
Affiliate Lecturer Discipline of Medicine, University of Adelaide
Apr 2014 → Apr 2020
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Research output: Contribution to journal › Article › peer-review
Eadie, L. (Recipient), 2004
Prize: Other distinction
Eadie, L. (Recipient), 11 Aug 2023
Prize
Eadie, L. (Participant)
Activity: Other
Eadie, L. (Participant)
Activity: Other
Eadie, L. (Participant)
Activity: Other
Eadie, L. (Participant)
Activity: Other
Eadie, L. (Participant)
Activity: Other